董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Annalisa Jenkins | 女 | Director | 60 | 14.69万美元 | 22.10 | 2025-10-29 |
| David York Norton | 男 | Director | 74 | 13.47万美元 | 24.98 | 2025-10-29 |
| Robert McQuade | 男 | Director | 68 | 14.39万美元 | 169.73 | 2025-10-29 |
| Linda McGoldrick | 女 | Director | 70 | 27.23万美元 | 10.26 | 2025-10-29 |
| Daphne Karydas | 女 | Director | 51 | 14.58万美元 | 1.16 | 2025-10-29 |
| Kabir Nath | 男 | Chief Executive Officer and Director | 60 | 210.47万美元 | 64.02 | 2025-10-29 |
| Wayne Riley | 男 | Director | 65 | 13.62万美元 | 9.73 | 2025-10-29 |
| Jeff Jonas | 男 | Director | -- | 24.65万美元 | 未持股 | 2025-10-29 |
| Gino Santini | 男 | Chair of the Board | 68 | 23.28万美元 | 1.30 | 2025-10-29 |
| Justin Gover | 男 | Director | 55 | 18.77万美元 | 未持股 | 2025-10-29 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Teri Loxam | 女 | Chief Financial Officer | 53 | 109.77万美元 | 5.27 | 2025-10-29 |
| Kabir Nath | 男 | Chief Executive Officer and Director | 60 | 210.47万美元 | 64.02 | 2025-10-29 |
| Guy Goodwin | 男 | Chief Medical Officer | 77 | 90.90万美元 | 21.49 | 2025-10-29 |
董事简历
中英对照 | 中文 | 英文- Annalisa Jenkins
-
Annalisa Jenkins，自2018年3月起担任Avrobio，Inc.董事会成员。从2017年11月到2019年4月，Jenkins博士担任PlaqueTec Ltd.的首席执行官，这是一家专注于冠状动脉疾病治疗和预防的生物技术公司。此前，Jenkins博士曾于2014年9月担任Dimension Therapeutics, Inc.的总裁兼首席执行官以及董事会成员，该公司是一家专注于与肝脏相关的罕见和代谢性疾病的生物技术公司，直至2017年11月将其出售给Ultragenyx药业制药公司。2013年10月至2014年3月，Jenkins博士担任生物制药公司Merck Serono Pharmaceuticals的执行副总裁兼全球研发主管。此前，2011年9月至2013年10月，她担任Merck Serono全球开发和医疗执行副总裁，并且是默沙东雪兰诺执行委员会成员。在此之前，Jenkins博士在生物制药公司百时美施贵宝公司从事了15年的职业生涯，2009年7月至2011年6月，她在该公司担任高级副总裁兼全球医疗事务主管。Jenkins士目前担任Genomics England的董事会成员，这是一家致力于推进100，000基因组项目的英国政府实体。Jenkins博士还在Oncimmune Holdings PLC（LSE：ONC）、Affimed N.V。（纳斯达克：AFMD）、Compass Pathways（纳斯达克：CMPS）、Mereo Biopharma Group PLC（纳斯达克：MREO）以及多家私营生物技术和生命科学公司的董事会任职，并担任多家非营利组织的受托人。Jenkins博士此前曾在多家生物技术和生命科学公司的董事会任职，包括AgeX Therapeutics公司（NYSE American：AGE）、Silence Therapeutics、Ardelyx, Inc.，TERM2，OncoSec医疗 Medical Incorporated，以及Sensyne Health PLC.，她还曾担任FDA科学委员会的委员会成员，该委员会就复杂的科学和技术问题向领导层提供建议。Jenkins博士毕业于伦敦大学圣巴塞洛缪医院，获得医学学位，随后在英国National Health服务中心接受心血管医学培训。在她职业生涯的早期，Jenkins博士曾在英国皇家海军担任医务官员。
Annalisa Jenkins has served as a member of Skye Bioscience, Inc.'s Board of Directors since February 2024. From November 2017 until April 2019, Dr. Jenkins served as the Chief Executive Officer of PlaqueTec Ltd., a biotechnology company focusing on coronary artery disease treatment and prevention. Previously, Dr. Jenkins served as the Chief Executive Officer and a member of the board of directors of Dimension Therapeutics, Inc. (Nasdaq: DMTX), a gene therapy company focused on rare and metabolic diseases associated with the liver, from September 2014 until its sale to Ultragenyx Pharmaceutical Inc. (Nasdaq: RARE) in November 2017. From October 2013 to March 2014, Dr. Jenkins served as Executive Vice President, Head of Global Research and Development for Merck Serono Pharmaceuticals, a biopharmaceutical company. Previously, from September 2011 to October 2013, she served as Merck Serono's Executive Vice President, Global Development and Medical, and was a member of Merck Serono's executive committee. Prior to that, Dr. Jenkins pursued a 15 year career at Bristol Myers Squibb Company, a biopharmaceutical company, where, from July 2009 to June 2011 she was a Senior Vice President and Head of Global Medical Affairs. Dr. Jenkins is currently a non executive director of Genomics England. Dr. Jenkins serves on the board of directors of Affimed GmbH (Nasdaq: AFMD), Mereo BioPharma Group plc (Nasdaq: MREO), Compass Pathways PLC (Nasdaq: CMPS) and a number of privately held biotechnology and life science companies, including the board of directors of four privately listed European based fund platforms investing into the life sciences sector. Previously within the past five years, Dr. Jenkins served on the board of directors of Ardelyx, Inc. (Nasdaq: ARDX), AgeX Therapeutics, Inc. (NYSE American: AGE), Avrobio, Inc. (Nasdaq: AVRO) and Oncimmune Holdings plc (LSE: ONC). Dr. Jenkins serves on a number of charitable boards, advisory boards and contributes publicly on leadership with purpose, social entrepreneurship, diversity and innovation. Dr. Jenkins graduated with a degree in medicine from St. Bartholomew's Hospital in the University of London and subsequently trained in cardiovascular medicine in the U.K. National Health Service. Earlier in her career, Dr. Jenkins served as a Medical Officer in the British Royal Navy during the Gulf Conflict, achieving the rank of Surgeon Lieutenant Commander. - Annalisa Jenkins，自2018年3月起担任Avrobio，Inc.董事会成员。从2017年11月到2019年4月，Jenkins博士担任PlaqueTec Ltd.的首席执行官，这是一家专注于冠状动脉疾病治疗和预防的生物技术公司。此前，Jenkins博士曾于2014年9月担任Dimension Therapeutics, Inc.的总裁兼首席执行官以及董事会成员，该公司是一家专注于与肝脏相关的罕见和代谢性疾病的生物技术公司，直至2017年11月将其出售给Ultragenyx药业制药公司。2013年10月至2014年3月，Jenkins博士担任生物制药公司Merck Serono Pharmaceuticals的执行副总裁兼全球研发主管。此前，2011年9月至2013年10月，她担任Merck Serono全球开发和医疗执行副总裁，并且是默沙东雪兰诺执行委员会成员。在此之前，Jenkins博士在生物制药公司百时美施贵宝公司从事了15年的职业生涯，2009年7月至2011年6月，她在该公司担任高级副总裁兼全球医疗事务主管。Jenkins士目前担任Genomics England的董事会成员，这是一家致力于推进100，000基因组项目的英国政府实体。Jenkins博士还在Oncimmune Holdings PLC（LSE：ONC）、Affimed N.V。（纳斯达克：AFMD）、Compass Pathways（纳斯达克：CMPS）、Mereo Biopharma Group PLC（纳斯达克：MREO）以及多家私营生物技术和生命科学公司的董事会任职，并担任多家非营利组织的受托人。Jenkins博士此前曾在多家生物技术和生命科学公司的董事会任职，包括AgeX Therapeutics公司（NYSE American：AGE）、Silence Therapeutics、Ardelyx, Inc.，TERM2，OncoSec医疗 Medical Incorporated，以及Sensyne Health PLC.，她还曾担任FDA科学委员会的委员会成员，该委员会就复杂的科学和技术问题向领导层提供建议。Jenkins博士毕业于伦敦大学圣巴塞洛缪医院，获得医学学位，随后在英国National Health服务中心接受心血管医学培训。在她职业生涯的早期，Jenkins博士曾在英国皇家海军担任医务官员。
- Annalisa Jenkins has served as a member of Skye Bioscience, Inc.'s Board of Directors since February 2024. From November 2017 until April 2019, Dr. Jenkins served as the Chief Executive Officer of PlaqueTec Ltd., a biotechnology company focusing on coronary artery disease treatment and prevention. Previously, Dr. Jenkins served as the Chief Executive Officer and a member of the board of directors of Dimension Therapeutics, Inc. (Nasdaq: DMTX), a gene therapy company focused on rare and metabolic diseases associated with the liver, from September 2014 until its sale to Ultragenyx Pharmaceutical Inc. (Nasdaq: RARE) in November 2017. From October 2013 to March 2014, Dr. Jenkins served as Executive Vice President, Head of Global Research and Development for Merck Serono Pharmaceuticals, a biopharmaceutical company. Previously, from September 2011 to October 2013, she served as Merck Serono's Executive Vice President, Global Development and Medical, and was a member of Merck Serono's executive committee. Prior to that, Dr. Jenkins pursued a 15 year career at Bristol Myers Squibb Company, a biopharmaceutical company, where, from July 2009 to June 2011 she was a Senior Vice President and Head of Global Medical Affairs. Dr. Jenkins is currently a non executive director of Genomics England. Dr. Jenkins serves on the board of directors of Affimed GmbH (Nasdaq: AFMD), Mereo BioPharma Group plc (Nasdaq: MREO), Compass Pathways PLC (Nasdaq: CMPS) and a number of privately held biotechnology and life science companies, including the board of directors of four privately listed European based fund platforms investing into the life sciences sector. Previously within the past five years, Dr. Jenkins served on the board of directors of Ardelyx, Inc. (Nasdaq: ARDX), AgeX Therapeutics, Inc. (NYSE American: AGE), Avrobio, Inc. (Nasdaq: AVRO) and Oncimmune Holdings plc (LSE: ONC). Dr. Jenkins serves on a number of charitable boards, advisory boards and contributes publicly on leadership with purpose, social entrepreneurship, diversity and innovation. Dr. Jenkins graduated with a degree in medicine from St. Bartholomew's Hospital in the University of London and subsequently trained in cardiovascular medicine in the U.K. National Health Service. Earlier in her career, Dr. Jenkins served as a Medical Officer in the British Royal Navy during the Gulf Conflict, achieving the rank of Surgeon Lieutenant Commander.
- David York Norton
-
David York Norton自2018年5月起担任我们的董事会成员。直到2011年9月退休，诺顿一直担任上市梦百合公司强生公司全球制药集团（Global Pharmaceuticals for McKinsey）董事长。诺顿于1979年开始了他的强生公司职业生涯，在该公司担任过多个职位，包括2006年至2009年担任CNS全球商业和运营公司集团主席，担任欧洲制药业务公司集团主席，从2004年到2006年担任中东和非洲地区，从2003年到2004年担任北美制药业务公司集团主席。诺顿先生目前Vivus，Inc.担任董事会主席。纳斯达克股票代码:VVUS，并担任Mallinckrodt，plc和Forepont Capital，LLC的董事会成员。Norton先生毕业于澳大利亚控制数据研究所（Control Data Institute）和英国分销贸易学院（College of Distributive Trades）。
David York Norton has served as a member of board of directors since May 2018. Until his retirement in September 2011 Mr. Norton was Company Group Chairman, Global Pharmaceuticals for Johnson & Johnson, a public healthcare company. Mr. Norton began his Johnson & Johnson career in 1979 and held a number of positions at the company, including Company Group Chairman, Worldwide Commercial and Operations for the CNS, Internal Medicine franchise from 2006 to 2009 Company Group Chairman for the pharmaceutical businesses in Europe, the Middle East and Africa from 2004 to 2006 and Company Group Chairman for the pharmaceutical businesses in North America from 2003 to 2004. Mr. Norton currently serves on the board of directors of Mallinckrodt, PLC and Forepont Capital, LLC. Mr. Norton is a graduate of Control Data Institute, Australia and the College of Distributive Trades, United Kingdom. - David York Norton自2018年5月起担任我们的董事会成员。直到2011年9月退休，诺顿一直担任上市梦百合公司强生公司全球制药集团（Global Pharmaceuticals for McKinsey）董事长。诺顿于1979年开始了他的强生公司职业生涯，在该公司担任过多个职位，包括2006年至2009年担任CNS全球商业和运营公司集团主席，担任欧洲制药业务公司集团主席，从2004年到2006年担任中东和非洲地区，从2003年到2004年担任北美制药业务公司集团主席。诺顿先生目前Vivus，Inc.担任董事会主席。纳斯达克股票代码:VVUS，并担任Mallinckrodt，plc和Forepont Capital，LLC的董事会成员。Norton先生毕业于澳大利亚控制数据研究所（Control Data Institute）和英国分销贸易学院（College of Distributive Trades）。
- David York Norton has served as a member of board of directors since May 2018. Until his retirement in September 2011 Mr. Norton was Company Group Chairman, Global Pharmaceuticals for Johnson & Johnson, a public healthcare company. Mr. Norton began his Johnson & Johnson career in 1979 and held a number of positions at the company, including Company Group Chairman, Worldwide Commercial and Operations for the CNS, Internal Medicine franchise from 2006 to 2009 Company Group Chairman for the pharmaceutical businesses in Europe, the Middle East and Africa from 2004 to 2006 and Company Group Chairman for the pharmaceutical businesses in North America from 2003 to 2004. Mr. Norton currently serves on the board of directors of Mallinckrodt, PLC and Forepont Capital, LLC. Mr. Norton is a graduate of Control Data Institute, Australia and the College of Distributive Trades, United Kingdom.
- Robert McQuade
-
Robert McQuade自2020年4月起担任我们的董事会成员。McQuade博士目前担任大冢制药开发与商业化公司（Otsuka Pharmaceutical Development&Commercialization，Inc.）的执行Vice President兼首席战略官，他自2004年以来一直在该公司任职。McQuade博士自2020年以来也是McQuade战略研究与开发有限责任公司中心的总裁。McQuade博士目前担任Otsuka美国制药公司、Astex制药公司、Astex制药公司、Avanir制药公司、Visterra，Inc.、Otsuka制药开发和商业化公司、南卡罗来纳医科大学研究与开发基金会、技术加速器公司和临床生物技术研究所的董事。McQuade博士在戴维森学院（Davidson College）获得生物学学位，并在北卡罗莱纳大学教堂山分校（University of North Carolina at Chapel Hill）完成生物化学博士学位。在加入Otsuka之前，McQuade博士曾在先灵葆雅公司（Schering-Plough Corp.）从事药物发现研究，并在百时美施贵宝公司（McKinsey）从事全球医疗事务。
Robert McQuade has served as a member of board of directors since April 2020. Dr. McQuade currently serves as the Executive Vice President & Chief Strategic Officer at Otsuka Pharmaceutical Development & Commercialization, Inc., or Otsuka, where he has served since 2004. Dr. McQuade is also the Officer and Manager of the McQuade Center for Strategic Research and Development LLC since February 2020. Dr. McQuade currently serves on the board of directors of Otsuka America Pharmaceutical, Inc., Astex Pharmaceutical, Inc., Astex Pharmaceutical, Ltd., Avanir Pharmaceuticals, Visterra, Inc., Otsuka Pharmaceutical Development & Commercialization, Inc., Medical University of South Carolina Foundation for Research and Development, The Technology Accelerator Co., and Clinical Biotechnology Research Institute. Dr. McQuade received his degree in biology from Davidson College and completed his Ph.D. in biochemistry from University of North Carolina at Chapel Hill. Prior to joining Otsuka, Dr. McQuade worked in drug discovery research at Schering-Plough Corp. and in global medical affairs at Bristol-Myers Squibb company. - Robert McQuade自2020年4月起担任我们的董事会成员。McQuade博士目前担任大冢制药开发与商业化公司（Otsuka Pharmaceutical Development&Commercialization，Inc.）的执行Vice President兼首席战略官，他自2004年以来一直在该公司任职。McQuade博士自2020年以来也是McQuade战略研究与开发有限责任公司中心的总裁。McQuade博士目前担任Otsuka美国制药公司、Astex制药公司、Astex制药公司、Avanir制药公司、Visterra，Inc.、Otsuka制药开发和商业化公司、南卡罗来纳医科大学研究与开发基金会、技术加速器公司和临床生物技术研究所的董事。McQuade博士在戴维森学院（Davidson College）获得生物学学位，并在北卡罗莱纳大学教堂山分校（University of North Carolina at Chapel Hill）完成生物化学博士学位。在加入Otsuka之前，McQuade博士曾在先灵葆雅公司（Schering-Plough Corp.）从事药物发现研究，并在百时美施贵宝公司（McKinsey）从事全球医疗事务。
- Robert McQuade has served as a member of board of directors since April 2020. Dr. McQuade currently serves as the Executive Vice President & Chief Strategic Officer at Otsuka Pharmaceutical Development & Commercialization, Inc., or Otsuka, where he has served since 2004. Dr. McQuade is also the Officer and Manager of the McQuade Center for Strategic Research and Development LLC since February 2020. Dr. McQuade currently serves on the board of directors of Otsuka America Pharmaceutical, Inc., Astex Pharmaceutical, Inc., Astex Pharmaceutical, Ltd., Avanir Pharmaceuticals, Visterra, Inc., Otsuka Pharmaceutical Development & Commercialization, Inc., Medical University of South Carolina Foundation for Research and Development, The Technology Accelerator Co., and Clinical Biotechnology Research Institute. Dr. McQuade received his degree in biology from Davidson College and completed his Ph.D. in biochemistry from University of North Carolina at Chapel Hill. Prior to joining Otsuka, Dr. McQuade worked in drug discovery research at Schering-Plough Corp. and in global medical affairs at Bristol-Myers Squibb company.
- Linda McGoldrick
-
Linda McGoldrick自2020年9月起担任公司董事。1985年，McGoldrick女士创立了Financial Health Associates International，目前担任其董事长兼首席执行官，这是一家专门从事梦百合和生命科学的战略咨询公司。从2019年4月至2019年12月，McGoldrick女士担任健康，技术和状态管理公司Zillion，Inc.的总裁兼临时首席执行官。在她的职业生涯中，她曾担任多个领导职务，包括Marsh-MMC Companies梦百合和生命科学行业实践的高级副总裁和国家发展总监，欧洲医疗设备公司Veos plc的国际运营和营销总监，以及Kaiser Permanente International的欧洲董事总经理。2018年，McGoldrick女士被马萨诸塞州州长任命为该州卫生信息技术委员会成员。McGoldrick女士曾担任美国，英国和欧洲众多上市和私人控股公司以及非营利组织的董事，目前任职于National Association of Corporate Directors的教员。McGoldrick女士在俄亥俄卫斯理大学（Ohio Wesleyan University）获得社会学文学学士学位，在宾夕法尼亚大学（University of Pennsylvania）获得社会工作硕士学位，在宾夕法尼亚大学沃顿商学院（Wharton School）获得管理学工商管理硕士学位。
Linda McGoldrick has served as a director of company since September 2020. In 1985 Ms. McGoldrick founded, and currently serves as Chairman and Chief Executive Officer of, Financial Health Associates International, a strategic consulting company specializing in healthcare and life sciences. From April 2019 through December 2019 Ms. McGoldrick served as President and interim Chief Executive Officer of Zillion, Inc., a health, technology and condition management company. Over her professional career, she has served in a number of leadership roles, including senior vice president and National Development director for the Healthcare and Life Sciences Industry Practices at Marsh-MMC Companies, international operations and marketing director of Veos plc, a European medical devices company, and managing director Europe for Kaiser Permanente International. In 2018 Ms. McGoldrick was appointed by the Governor of Massachusetts to serve on the Commonwealth's Health Information Technology Commission. Ms. McGoldrick has served as a director of numerous publicly traded and private held companies and non-profit organizations in the U.S., UK and Europe and currently serves on the faculty of the National Association of Corporate Directors. Ms. McGoldrick received her bachelor of arts in sociology from Ohio Wesleyan University and master of social work from the University of Pennsylvania and master of business administration in management from the Wharton School, University of Pennsylvania. - Linda McGoldrick自2020年9月起担任公司董事。1985年，McGoldrick女士创立了Financial Health Associates International，目前担任其董事长兼首席执行官，这是一家专门从事梦百合和生命科学的战略咨询公司。从2019年4月至2019年12月，McGoldrick女士担任健康，技术和状态管理公司Zillion，Inc.的总裁兼临时首席执行官。在她的职业生涯中，她曾担任多个领导职务，包括Marsh-MMC Companies梦百合和生命科学行业实践的高级副总裁和国家发展总监，欧洲医疗设备公司Veos plc的国际运营和营销总监，以及Kaiser Permanente International的欧洲董事总经理。2018年，McGoldrick女士被马萨诸塞州州长任命为该州卫生信息技术委员会成员。McGoldrick女士曾担任美国，英国和欧洲众多上市和私人控股公司以及非营利组织的董事，目前任职于National Association of Corporate Directors的教员。McGoldrick女士在俄亥俄卫斯理大学（Ohio Wesleyan University）获得社会学文学学士学位，在宾夕法尼亚大学（University of Pennsylvania）获得社会工作硕士学位，在宾夕法尼亚大学沃顿商学院（Wharton School）获得管理学工商管理硕士学位。
- Linda McGoldrick has served as a director of company since September 2020. In 1985 Ms. McGoldrick founded, and currently serves as Chairman and Chief Executive Officer of, Financial Health Associates International, a strategic consulting company specializing in healthcare and life sciences. From April 2019 through December 2019 Ms. McGoldrick served as President and interim Chief Executive Officer of Zillion, Inc., a health, technology and condition management company. Over her professional career, she has served in a number of leadership roles, including senior vice president and National Development director for the Healthcare and Life Sciences Industry Practices at Marsh-MMC Companies, international operations and marketing director of Veos plc, a European medical devices company, and managing director Europe for Kaiser Permanente International. In 2018 Ms. McGoldrick was appointed by the Governor of Massachusetts to serve on the Commonwealth's Health Information Technology Commission. Ms. McGoldrick has served as a director of numerous publicly traded and private held companies and non-profit organizations in the U.S., UK and Europe and currently serves on the faculty of the National Association of Corporate Directors. Ms. McGoldrick received her bachelor of arts in sociology from Ohio Wesleyan University and master of social work from the University of Pennsylvania and master of business administration in management from the Wharton School, University of Pennsylvania.
- Daphne Karydas
-
Daphne Karydas，我们的董事会成员，自2020年7月起担任Syndax Pharmaceuticals的首席财务官，此前从2018年12月到2020年5月担任Allergan的企业财务规划与分析和战略高级副总裁，直到最近被AbbVie收购，自2017年4月至2018年12月担任全球投资者关系和战略高级副总裁。在这些职位上，Karydas女士负责监管Allergan’；的长期财务和业务战略，并领导与投资界的接触和业务战略开发。在Syndax Pharmaceuticals和Allergan担任运营职务之前，Karydas女士在投资银行和资产管理职位上工作了大约16年，专注于医疗保健领域，包括生物制药、生命科学和医疗技术以及医疗保健服务。在加入Allergan之前，Karydas女士担任J.P.Morgan Asset Management的执行董事和高级医疗保健分析师。此前，Karydas女士是the Boston Company Asset Management（纽约梅隆公司）的投资组合经理和高级医疗保健分析师。此前，Karydas女士是Goldman Sachs Asset Management的副总裁，专注于医疗保健，也是Goldman Sachs’；医疗保健投资银行团队的成员。在加入高盛（Goldman Sachs）之前，她是默克公司（Merck&Co.）的项目化学工程师，专注于新型疫苗的工艺开发。Karydas女士在麻省理工学院获得化学工程学士和硕士学位，在哈佛商学院获得工商管理硕士学位。
Daphne Karydas , a member of Eucrates Biomedical Acquisition Corp. Board of Directors, has served as the Chief Financial Officer and Chief Operating Officer of Flare Therapeutics since October 2021. Previously, she served as the Chief Financial Officer of Syndax Pharmaceuticals from July 2020 through October 2021, and also held positions as the Senior Vice President of Corporate Strategy, Corporate Financial Planning and Analysis and Head of Global Investor Relations at Allergen from April 2017 to May 2020, until its acquisition by Abbvie. In these roles, Ms. Karydas oversaw Allergen's long-term financial and business strategy, and also led engagement with the investment community and business strategy development. Prior to her operating roles at Syndax Pharmaceuticals and Allergan, Ms. Karydas spent approximately 16 years in investment banking and asset management roles, focused exclusively in the healthcare space, including biopharmaceuticals, life sciences & medical technologies and healthcare services. Prior to joining Allergan, Ms. Karydas served as Executive Director and Senior Healthcare Analyst at J.P. Morgan Asset Management. Previously, Ms. Karydas was a Portfolio Manager and Senior Healthcare Analyst at The Boston Company Asset Management, a BNY Mellon company. Earlier, Ms. Karydas was a Vice President at Goldman Sachs Asset Management focused on healthcare, as well as a member of Goldman Sachs' healthcare investment banking team. Before joining Goldman Sachs, she was a Project Chemical Engineer at Merck & Co. where she focused on process development for novel vaccines. Ms. Karydas received a B.A. and M.S. in chemical engineering from the Massachusetts Institute of Technology and an M.B.A. from Harvard Business School. - Daphne Karydas，我们的董事会成员，自2020年7月起担任Syndax Pharmaceuticals的首席财务官，此前从2018年12月到2020年5月担任Allergan的企业财务规划与分析和战略高级副总裁，直到最近被AbbVie收购，自2017年4月至2018年12月担任全球投资者关系和战略高级副总裁。在这些职位上，Karydas女士负责监管Allergan’；的长期财务和业务战略，并领导与投资界的接触和业务战略开发。在Syndax Pharmaceuticals和Allergan担任运营职务之前，Karydas女士在投资银行和资产管理职位上工作了大约16年，专注于医疗保健领域，包括生物制药、生命科学和医疗技术以及医疗保健服务。在加入Allergan之前，Karydas女士担任J.P.Morgan Asset Management的执行董事和高级医疗保健分析师。此前，Karydas女士是the Boston Company Asset Management（纽约梅隆公司）的投资组合经理和高级医疗保健分析师。此前，Karydas女士是Goldman Sachs Asset Management的副总裁，专注于医疗保健，也是Goldman Sachs’；医疗保健投资银行团队的成员。在加入高盛（Goldman Sachs）之前，她是默克公司（Merck&Co.）的项目化学工程师，专注于新型疫苗的工艺开发。Karydas女士在麻省理工学院获得化学工程学士和硕士学位，在哈佛商学院获得工商管理硕士学位。
- Daphne Karydas , a member of Eucrates Biomedical Acquisition Corp. Board of Directors, has served as the Chief Financial Officer and Chief Operating Officer of Flare Therapeutics since October 2021. Previously, she served as the Chief Financial Officer of Syndax Pharmaceuticals from July 2020 through October 2021, and also held positions as the Senior Vice President of Corporate Strategy, Corporate Financial Planning and Analysis and Head of Global Investor Relations at Allergen from April 2017 to May 2020, until its acquisition by Abbvie. In these roles, Ms. Karydas oversaw Allergen's long-term financial and business strategy, and also led engagement with the investment community and business strategy development. Prior to her operating roles at Syndax Pharmaceuticals and Allergan, Ms. Karydas spent approximately 16 years in investment banking and asset management roles, focused exclusively in the healthcare space, including biopharmaceuticals, life sciences & medical technologies and healthcare services. Prior to joining Allergan, Ms. Karydas served as Executive Director and Senior Healthcare Analyst at J.P. Morgan Asset Management. Previously, Ms. Karydas was a Portfolio Manager and Senior Healthcare Analyst at The Boston Company Asset Management, a BNY Mellon company. Earlier, Ms. Karydas was a Vice President at Goldman Sachs Asset Management focused on healthcare, as well as a member of Goldman Sachs' healthcare investment banking team. Before joining Goldman Sachs, she was a Project Chemical Engineer at Merck & Co. where she focused on process development for novel vaccines. Ms. Karydas received a B.A. and M.S. in chemical engineering from the Massachusetts Institute of Technology and an M.B.A. from Harvard Business School.
- Kabir Nath
-
Kabir Nath，自2022年8月起担任首席执行官和董事会成员。此前的2016年3月至2022年7月，Nath先生在大冢控股有限公司担任的职务越来越具有责任感和领导力，该公司是一家在东京证券交易所上市的全球领先的医疗保健集团（JP 4578）。最近，从2020年3月到2022年7月，Nath先生担任Otsuka全球制药高级董事总经理。从2016年3月到2022年4月，Nath先生担任Otsuka北美制药业务的总裁兼首席执行官。在加入大冢之前，从2003年到2015年12月，Nath先生在百时美施贵宝公司（纽约证券交易所代码：BMS）担任的职责和领导职务越来越多。Nath先生目前担任美国预防自杀基金会（AFSP）的董事会成员，该基金会是一家领先的预防自杀组织。Nath先生拥有剑桥大学国王学院的硕士学位和欧洲工商管理学院的工商管理硕士学位。
Kabir Nath,has served as Chief Executive Officer and a member of Board since August 2022. Previously from March 2016 until July 2022, Mr. Nath held positions of increasing responsibility and leadership at Otsuka Holdings Co., Ltd., a leading global healthcare group listed on the Tokyo Stock Exchange (JP 4578). Most recently, from March 2020 until July 2022, Mr. Nath served as senior managing director of global pharmaceuticals at Otsuka. From March 2016 until April 2022, Mr. Nath served as president and chief executive officer of Otsuka's North America Pharmaceutical Business. Prior to Otsuka, from 2003 until December 2015, Mr. Nath held positions of increasing responsibility and leadership at Bristol-Myers Squibb Company (NYSE: BMS). Mr. Nath currently serves on the board of directors of the American Foundation for Suicide Prevention (AFSP), a leading suicide prevention organization. Mr. Nath holds an M.A. from King's College, University of Cambridge, and an M.B.A. from INSEAD. - Kabir Nath，自2022年8月起担任首席执行官和董事会成员。此前的2016年3月至2022年7月，Nath先生在大冢控股有限公司担任的职务越来越具有责任感和领导力，该公司是一家在东京证券交易所上市的全球领先的医疗保健集团（JP 4578）。最近，从2020年3月到2022年7月，Nath先生担任Otsuka全球制药高级董事总经理。从2016年3月到2022年4月，Nath先生担任Otsuka北美制药业务的总裁兼首席执行官。在加入大冢之前，从2003年到2015年12月，Nath先生在百时美施贵宝公司（纽约证券交易所代码：BMS）担任的职责和领导职务越来越多。Nath先生目前担任美国预防自杀基金会（AFSP）的董事会成员，该基金会是一家领先的预防自杀组织。Nath先生拥有剑桥大学国王学院的硕士学位和欧洲工商管理学院的工商管理硕士学位。
- Kabir Nath,has served as Chief Executive Officer and a member of Board since August 2022. Previously from March 2016 until July 2022, Mr. Nath held positions of increasing responsibility and leadership at Otsuka Holdings Co., Ltd., a leading global healthcare group listed on the Tokyo Stock Exchange (JP 4578). Most recently, from March 2020 until July 2022, Mr. Nath served as senior managing director of global pharmaceuticals at Otsuka. From March 2016 until April 2022, Mr. Nath served as president and chief executive officer of Otsuka's North America Pharmaceutical Business. Prior to Otsuka, from 2003 until December 2015, Mr. Nath held positions of increasing responsibility and leadership at Bristol-Myers Squibb Company (NYSE: BMS). Mr. Nath currently serves on the board of directors of the American Foundation for Suicide Prevention (AFSP), a leading suicide prevention organization. Mr. Nath holds an M.A. from King's College, University of Cambridge, and an M.B.A. from INSEAD.
- Wayne Riley
-
Wayne Riley，自2021年3月起担任董事会成员。Riley博士担任纽约州立大学（SUNY）位于美国纽约州布鲁克林区的Downstate Health Sciences大学校长，担任该大学内科、健康政策和管理方面的终身教授职务，自2017年1月起任职。在此之前，Riley博士曾于2007年7月至2017年6月担任范德比尔特大学医学临床教授和卫生政策兼职教授，并于2007年1月至2013年7月担任梅哈里医学院校长兼首席执行官。此外，Riley博士目前还担任美国国家医学研究院当选成员、美国医疗保险支付咨询委员会委员、纽约医学院董事会主席、医疗行政人员协会主席、北美领先的医师高管组织、美国内科医生学院名誉院长。Riley博士还是HCA健康护理公司（纽约证券交易所代码：HCA）的董事会成员，担任患者安全与质量委员会主席、审计与合规委员会以及提名与公司治理委员会成员以及HeartFlow，Inc.的董事会成员。他此前还曾担任福泰制药 Inc.（纳斯达克：VRTX）的董事。Riley博士拥有耶鲁大学学士学位、杜兰大学公共卫生与热带医学学院公共卫生硕士学位、莫尔豪斯医学院医学博士学位和莱斯大学MBA学位。
Wayne Riley,has served as a member of Board since March 2021. Dr. Riley serves as the President of the State University of New York (SUNY) Downstate Health Sciences University, Brooklyn, NY, USA where he holds tenured professorships in internal medicine, and health policy and management and has served since January 2017. Prior to this, Dr. Riley served as a clinical professor of medicine and adjunct professor of health policy at Vanderbilt University from July 2007 until June 2017, and as President and Chief Executive Officer of Meharry Medical College from January 2007 until July 2013. In addition, Dr. Riley currently serves as an elected member of the U.S. National Academy of Medicine, a Commissioner of the U.S. Medicare Payment Advisory Commission, Chair of the Board of the New York Academy of Medicine, President of the Society of Medical Administrators, an organization of leading North American physician executives, and a President Emeritus of the American College of Physicians. Dr. Riley is also a member of the board of directors of HCA Healthcare Inc. (NYSE: HCA), where he serves as Chair of the Patient Safety & Quality Committee and a member of the Audit & Compliance and Nominating & Corporate Governance Committees and a member of the board of directors of HeartFlow, Inc. He also previously served as a Director of Vertex Pharmaceuticals Inc. (Nasdaq: VRTX). Dr. Riley holds a BA from Yale University, Masters in Public Health from the Tulane University School of Public Health and Tropical Medicine, M.D. from the Morehouse School of Medicine, and MBA from Rice University. - Wayne Riley，自2021年3月起担任董事会成员。Riley博士担任纽约州立大学（SUNY）位于美国纽约州布鲁克林区的Downstate Health Sciences大学校长，担任该大学内科、健康政策和管理方面的终身教授职务，自2017年1月起任职。在此之前，Riley博士曾于2007年7月至2017年6月担任范德比尔特大学医学临床教授和卫生政策兼职教授，并于2007年1月至2013年7月担任梅哈里医学院校长兼首席执行官。此外，Riley博士目前还担任美国国家医学研究院当选成员、美国医疗保险支付咨询委员会委员、纽约医学院董事会主席、医疗行政人员协会主席、北美领先的医师高管组织、美国内科医生学院名誉院长。Riley博士还是HCA健康护理公司（纽约证券交易所代码：HCA）的董事会成员，担任患者安全与质量委员会主席、审计与合规委员会以及提名与公司治理委员会成员以及HeartFlow，Inc.的董事会成员。他此前还曾担任福泰制药 Inc.（纳斯达克：VRTX）的董事。Riley博士拥有耶鲁大学学士学位、杜兰大学公共卫生与热带医学学院公共卫生硕士学位、莫尔豪斯医学院医学博士学位和莱斯大学MBA学位。
- Wayne Riley,has served as a member of Board since March 2021. Dr. Riley serves as the President of the State University of New York (SUNY) Downstate Health Sciences University, Brooklyn, NY, USA where he holds tenured professorships in internal medicine, and health policy and management and has served since January 2017. Prior to this, Dr. Riley served as a clinical professor of medicine and adjunct professor of health policy at Vanderbilt University from July 2007 until June 2017, and as President and Chief Executive Officer of Meharry Medical College from January 2007 until July 2013. In addition, Dr. Riley currently serves as an elected member of the U.S. National Academy of Medicine, a Commissioner of the U.S. Medicare Payment Advisory Commission, Chair of the Board of the New York Academy of Medicine, President of the Society of Medical Administrators, an organization of leading North American physician executives, and a President Emeritus of the American College of Physicians. Dr. Riley is also a member of the board of directors of HCA Healthcare Inc. (NYSE: HCA), where he serves as Chair of the Patient Safety & Quality Committee and a member of the Audit & Compliance and Nominating & Corporate Governance Committees and a member of the board of directors of HeartFlow, Inc. He also previously served as a Director of Vertex Pharmaceuticals Inc. (Nasdaq: VRTX). Dr. Riley holds a BA from Yale University, Masters in Public Health from the Tulane University School of Public Health and Tropical Medicine, M.D. from the Morehouse School of Medicine, and MBA from Rice University.
- Jeff Jonas
-
Jeff Jonas，自2024年1月起担任生命科学风险投资公司Cure Ventures的合伙人。从2022年11月到2023年9月，乔纳斯博士担任波士顿地区生物技术孵化器ABio-X的首席执行官。此前，Jonas博士于2020年12月至2022年11月期间担任上市生物制药公司Sage Therapeutics, Inc.（后被Supernus Pharmaceuticals, Inc.（SUPN）（“Sage”）收购）的首席创新官，并于2013年8月至2020年12月期间担任Sage的首席执行官兼总裁。Jonas博士目前在Generation Bio Co（纳斯达克：GBIO）的董事会任职，自2018年以来一直服务于该公司以及多家私营生物技术公司。他目前担任Delix Therapeutics的科学顾问委员会成员。此前，Jonas博士曾于2013年8月至2024年12月担任Sage的董事会成员，并于2018年10月担任上市生物制药公司Karuna Pharmaceuticals，Inc.的董事会成员，直至2024年3月被百时美施贵宝（NYSE：BMY）收购。乔纳斯博士获得了阿默斯特学院的学士学位和哈佛医学院的医学博士学位。他在哈佛医学院完成了精神病学住院医师，并在哈佛医学院麦克莱恩医院担任心理药理学首席住院医师。
Jeff Jonas,has served as a partner at Cure Ventures, a life sciences venture capital firm, since January 2024. From November 2022 until September 2023, Dr. Jonas served as the chief executive officer of ABio-X, a Boston area biotechnology incubator. Previously, Dr. Jonas served as the chief innovation officer of Sage Therapeutics, Inc., a publicly-traded biopharmaceutical company (subsequently acquired by Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN) ("Sage")), from December 2020 to November 2022 and as the chief executive officer and president of Sage from August 2013 to December 2020. Dr. Jonas currently serves on the board of directors of Generation Bio Co (Nasdaq: GBIO) where he has served since 2018 and multiple private biotechnology companies. He currently serves as a member of the scientific advisory board for Delix Therapeutics. Previously, Dr. Jonas served on the boards of directors of Sage, from August 2013 to December 2024 and of Karuna Pharmaceuticals, Inc., a publicly-traded biopharmaceutical company, from October 2018 until its acquisition by Bristol Myers Squibb (NYSE: BMY) in March 2024. Dr. Jonas earned his B.A. from Amherst College and M.D. from Harvard Medical School. He completed a residency in psychiatry at Harvard Medical School, and he served as chief resident in psychopharmacology at McLean Hospital, Harvard Medical School. - Jeff Jonas，自2024年1月起担任生命科学风险投资公司Cure Ventures的合伙人。从2022年11月到2023年9月，乔纳斯博士担任波士顿地区生物技术孵化器ABio-X的首席执行官。此前，Jonas博士于2020年12月至2022年11月期间担任上市生物制药公司Sage Therapeutics, Inc.（后被Supernus Pharmaceuticals, Inc.（SUPN）（“Sage”）收购）的首席创新官，并于2013年8月至2020年12月期间担任Sage的首席执行官兼总裁。Jonas博士目前在Generation Bio Co（纳斯达克：GBIO）的董事会任职，自2018年以来一直服务于该公司以及多家私营生物技术公司。他目前担任Delix Therapeutics的科学顾问委员会成员。此前，Jonas博士曾于2013年8月至2024年12月担任Sage的董事会成员，并于2018年10月担任上市生物制药公司Karuna Pharmaceuticals，Inc.的董事会成员，直至2024年3月被百时美施贵宝（NYSE：BMY）收购。乔纳斯博士获得了阿默斯特学院的学士学位和哈佛医学院的医学博士学位。他在哈佛医学院完成了精神病学住院医师，并在哈佛医学院麦克莱恩医院担任心理药理学首席住院医师。
- Jeff Jonas,has served as a partner at Cure Ventures, a life sciences venture capital firm, since January 2024. From November 2022 until September 2023, Dr. Jonas served as the chief executive officer of ABio-X, a Boston area biotechnology incubator. Previously, Dr. Jonas served as the chief innovation officer of Sage Therapeutics, Inc., a publicly-traded biopharmaceutical company (subsequently acquired by Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN) ("Sage")), from December 2020 to November 2022 and as the chief executive officer and president of Sage from August 2013 to December 2020. Dr. Jonas currently serves on the board of directors of Generation Bio Co (Nasdaq: GBIO) where he has served since 2018 and multiple private biotechnology companies. He currently serves as a member of the scientific advisory board for Delix Therapeutics. Previously, Dr. Jonas served on the boards of directors of Sage, from August 2013 to December 2024 and of Karuna Pharmaceuticals, Inc., a publicly-traded biopharmaceutical company, from October 2018 until its acquisition by Bristol Myers Squibb (NYSE: BMY) in March 2024. Dr. Jonas earned his B.A. from Amherst College and M.D. from Harvard Medical School. He completed a residency in psychiatry at Harvard Medical School, and he served as chief resident in psychopharmacology at McLean Hospital, Harvard Medical School.
- Gino Santini
-
Gino Santini，自2012年3月起在董事会任职。目前，他在 AMAG Pharmaceuticals有限公司和Allena Pharmaceuticals有限公司董事会任职，且从Eli Lilly and Company（Lilly）退休，在此他工作了30年之久。在Lilly的任期内，他担任了责任越来越大的职务，包括许多国际地区的经理、女性健康特许的总裁，以及美国运营总裁。他在Lilly担任公司执行委员会董事及企业战略和业务发展高级副总裁。他精通四门语言，且持有博洛尼亚大学（ the University of Bologna）机械工程学士学位和罗切斯特大学（ the University of Rochester）工商管理硕士学位。
Gino Santini,currently serves on the boards of directors of Intercept Pharmaceuticals, Inc. and Collegium Pharmaceutical, Inc., both of which are public biopharma companies. Mr. Santini also serves on the boards of directors of Artax Biopharma Inc. and Enalare Therapeutics, Inc., each a private biopharma company, and is retired from a distinguished career with Eli Lilly and Company. He served as chairman of the board of directors of AMAG Pharmaceuticals, Inc., previously a public biopharma company, from February 2012 until November 2020, when AMAG was acquired by Covis Group S. à r.l., and on the board of directors of Allena Pharmaceuticals, Inc., a public biopharma company, from February 2012 until September 2022. During his tenure at Eli Lilly and Company from June 1983 to December 2010, Mr. Santini held various leadership positions. Mr. Santini, fluent in four languages, holds an undergraduate degree in mechanical engineering from the University of Bologna and a master of business administration degree from the University of Rochester. - Gino Santini，自2012年3月起在董事会任职。目前，他在 AMAG Pharmaceuticals有限公司和Allena Pharmaceuticals有限公司董事会任职，且从Eli Lilly and Company（Lilly）退休，在此他工作了30年之久。在Lilly的任期内，他担任了责任越来越大的职务，包括许多国际地区的经理、女性健康特许的总裁，以及美国运营总裁。他在Lilly担任公司执行委员会董事及企业战略和业务发展高级副总裁。他精通四门语言，且持有博洛尼亚大学（ the University of Bologna）机械工程学士学位和罗切斯特大学（ the University of Rochester）工商管理硕士学位。
- Gino Santini,currently serves on the boards of directors of Intercept Pharmaceuticals, Inc. and Collegium Pharmaceutical, Inc., both of which are public biopharma companies. Mr. Santini also serves on the boards of directors of Artax Biopharma Inc. and Enalare Therapeutics, Inc., each a private biopharma company, and is retired from a distinguished career with Eli Lilly and Company. He served as chairman of the board of directors of AMAG Pharmaceuticals, Inc., previously a public biopharma company, from February 2012 until November 2020, when AMAG was acquired by Covis Group S. à r.l., and on the board of directors of Allena Pharmaceuticals, Inc., a public biopharma company, from February 2012 until September 2022. During his tenure at Eli Lilly and Company from June 1983 to December 2010, Mr. Santini held various leadership positions. Mr. Santini, fluent in four languages, holds an undergraduate degree in mechanical engineering from the University of Bologna and a master of business administration degree from the University of Rochester.
- Justin Gover
-
1999年1月以来，Justin Gover担任首席执行官。他拥有17年制药行业的经验。作为一名首席执行官，他负责业务运行以及领先的股本融资和商业开发活动。从1995年到1997年，他担任道德控股有限公司负责人，他负责战略活动，包括并购、战略投资、股权融资和投资者关系。他拥有欧洲工商管理学院硕士学位和布里斯托尔大学的理学学士学位。
Justin Gover has served as Chief Executive Officer of the Company since January 1999 shortly after the Company was founded.As Chief Executive Officer, Mr. Gover has been the lead executive responsible for running the Company's operations, as well as leading equity financings, strategy and business development activities. In 2001 he led the Company's initial public offering on the AIM stock exchange in London, and in 2013 led the Company's initial public offering in the U.S. on Nasdaq. In total, he has led equity financings which have raised over $1 billion for the Company. In 2015 Mr. Gover relocated to the U.S. to open the Company's U.S. headquarters in California.Prior to joining the Company, Mr. Gover was Head of Corporate Affairs at Amarin, where he was responsible for the company's strategic corporate activities, including mergers and acquisitions, strategic investments, equity financings and investor relations. Mr. Gover serves on the board of directors of the Biotechnology Innovation Organization. He holds an M.B.A. from the INSEAD business school in France and a BSc Hons from Bristol University. - 1999年1月以来，Justin Gover担任首席执行官。他拥有17年制药行业的经验。作为一名首席执行官，他负责业务运行以及领先的股本融资和商业开发活动。从1995年到1997年，他担任道德控股有限公司负责人，他负责战略活动，包括并购、战略投资、股权融资和投资者关系。他拥有欧洲工商管理学院硕士学位和布里斯托尔大学的理学学士学位。
- Justin Gover has served as Chief Executive Officer of the Company since January 1999 shortly after the Company was founded.As Chief Executive Officer, Mr. Gover has been the lead executive responsible for running the Company's operations, as well as leading equity financings, strategy and business development activities. In 2001 he led the Company's initial public offering on the AIM stock exchange in London, and in 2013 led the Company's initial public offering in the U.S. on Nasdaq. In total, he has led equity financings which have raised over $1 billion for the Company. In 2015 Mr. Gover relocated to the U.S. to open the Company's U.S. headquarters in California.Prior to joining the Company, Mr. Gover was Head of Corporate Affairs at Amarin, where he was responsible for the company's strategic corporate activities, including mergers and acquisitions, strategic investments, equity financings and investor relations. Mr. Gover serves on the board of directors of the Biotechnology Innovation Organization. He holds an M.B.A. from the INSEAD business school in France and a BSc Hons from Bristol University.
高管简历
中英对照 | 中文 | 英文- Teri Loxam
Teri Loxam自2019年9月起担任我们的首席财务官。在加入我们之前，Loxam女士于2015年8月至2019年8月在全球梦百合公司默克制药公司担任投资者关系和全球沟通高级副总裁。在此之前，Loxam从2012年7月到2015年8月担任IMAX（一家娱乐技术公司）投资者关系Vice President。2001年6月至2012年7月，Loxam女士在全球梦百合公司百时美施贵宝（Bristol-Myers Squibb）的战略、财务和投资者关系方面承担了越来越多的责任。Loxam女士拥有University of California，Irvine，Paul Merage School of Business的工商管理硕士学位和工商管理硕士学位。来自维多利亚大学。
Teri Loxam has served as our Chief Financial Officer since September 2019. Before joining us, from August 2015 to August 2019 Ms. Loxam was at Merck & Co., Inc., a global healthcare company, where she served as Senior Vice President of Investor Relations and Global Communications. Before that, from July 2012 to August 2015 Ms. Loxam served as Vice President of Investor Relations at IMAX, an entertainment technology company. From June 2001 to July 2012 Ms. Loxam had a number of roles of increasing responsibility across Strategy, Treasury and Investor Relations at Bristol-Myers Squibb, a global healthcare company. Ms. Loxam holds an M.B.A. from the University of California, Irvine, Paul Merage School of Business, and a B.Sc. from the University of Victoria.- Teri Loxam自2019年9月起担任我们的首席财务官。在加入我们之前，Loxam女士于2015年8月至2019年8月在全球梦百合公司默克制药公司担任投资者关系和全球沟通高级副总裁。在此之前，Loxam从2012年7月到2015年8月担任IMAX（一家娱乐技术公司）投资者关系Vice President。2001年6月至2012年7月，Loxam女士在全球梦百合公司百时美施贵宝（Bristol-Myers Squibb）的战略、财务和投资者关系方面承担了越来越多的责任。Loxam女士拥有University of California，Irvine，Paul Merage School of Business的工商管理硕士学位和工商管理硕士学位。来自维多利亚大学。
- Teri Loxam has served as our Chief Financial Officer since September 2019. Before joining us, from August 2015 to August 2019 Ms. Loxam was at Merck & Co., Inc., a global healthcare company, where she served as Senior Vice President of Investor Relations and Global Communications. Before that, from July 2012 to August 2015 Ms. Loxam served as Vice President of Investor Relations at IMAX, an entertainment technology company. From June 2001 to July 2012 Ms. Loxam had a number of roles of increasing responsibility across Strategy, Treasury and Investor Relations at Bristol-Myers Squibb, a global healthcare company. Ms. Loxam holds an M.B.A. from the University of California, Irvine, Paul Merage School of Business, and a B.Sc. from the University of Victoria.
- Kabir Nath
Kabir Nath，自2022年8月起担任首席执行官和董事会成员。此前的2016年3月至2022年7月，Nath先生在大冢控股有限公司担任的职务越来越具有责任感和领导力，该公司是一家在东京证券交易所上市的全球领先的医疗保健集团（JP 4578）。最近，从2020年3月到2022年7月，Nath先生担任Otsuka全球制药高级董事总经理。从2016年3月到2022年4月，Nath先生担任Otsuka北美制药业务的总裁兼首席执行官。在加入大冢之前，从2003年到2015年12月，Nath先生在百时美施贵宝公司（纽约证券交易所代码：BMS）担任的职责和领导职务越来越多。Nath先生目前担任美国预防自杀基金会（AFSP）的董事会成员，该基金会是一家领先的预防自杀组织。Nath先生拥有剑桥大学国王学院的硕士学位和欧洲工商管理学院的工商管理硕士学位。
Kabir Nath,has served as Chief Executive Officer and a member of Board since August 2022. Previously from March 2016 until July 2022, Mr. Nath held positions of increasing responsibility and leadership at Otsuka Holdings Co., Ltd., a leading global healthcare group listed on the Tokyo Stock Exchange (JP 4578). Most recently, from March 2020 until July 2022, Mr. Nath served as senior managing director of global pharmaceuticals at Otsuka. From March 2016 until April 2022, Mr. Nath served as president and chief executive officer of Otsuka's North America Pharmaceutical Business. Prior to Otsuka, from 2003 until December 2015, Mr. Nath held positions of increasing responsibility and leadership at Bristol-Myers Squibb Company (NYSE: BMS). Mr. Nath currently serves on the board of directors of the American Foundation for Suicide Prevention (AFSP), a leading suicide prevention organization. Mr. Nath holds an M.A. from King's College, University of Cambridge, and an M.B.A. from INSEAD.- Kabir Nath，自2022年8月起担任首席执行官和董事会成员。此前的2016年3月至2022年7月，Nath先生在大冢控股有限公司担任的职务越来越具有责任感和领导力，该公司是一家在东京证券交易所上市的全球领先的医疗保健集团（JP 4578）。最近，从2020年3月到2022年7月，Nath先生担任Otsuka全球制药高级董事总经理。从2016年3月到2022年4月，Nath先生担任Otsuka北美制药业务的总裁兼首席执行官。在加入大冢之前，从2003年到2015年12月，Nath先生在百时美施贵宝公司（纽约证券交易所代码：BMS）担任的职责和领导职务越来越多。Nath先生目前担任美国预防自杀基金会（AFSP）的董事会成员，该基金会是一家领先的预防自杀组织。Nath先生拥有剑桥大学国王学院的硕士学位和欧洲工商管理学院的工商管理硕士学位。
- Kabir Nath,has served as Chief Executive Officer and a member of Board since August 2022. Previously from March 2016 until July 2022, Mr. Nath held positions of increasing responsibility and leadership at Otsuka Holdings Co., Ltd., a leading global healthcare group listed on the Tokyo Stock Exchange (JP 4578). Most recently, from March 2020 until July 2022, Mr. Nath served as senior managing director of global pharmaceuticals at Otsuka. From March 2016 until April 2022, Mr. Nath served as president and chief executive officer of Otsuka's North America Pharmaceutical Business. Prior to Otsuka, from 2003 until December 2015, Mr. Nath held positions of increasing responsibility and leadership at Bristol-Myers Squibb Company (NYSE: BMS). Mr. Nath currently serves on the board of directors of the American Foundation for Suicide Prevention (AFSP), a leading suicide prevention organization. Mr. Nath holds an M.A. from King's College, University of Cambridge, and an M.B.A. from INSEAD.
- Guy Goodwin
Guy Goodwin，自2021年8月起担任首席医疗官。古德温博士目前担任牛津大学精神病学名誉教授，自1996年10月起担任该大学精神病学教授。此外，古德温博士还曾在P1vital担任医疗主任，他在2018年4月至2021年7月期间在那里工作。古德温博士此前曾担任WA Handley精神病学主席和牛津大学精神病学系主任。古德温博士是美国神经精神药理学学院医学科学院院士，曾任英国心理药理学协会和欧洲神经精神药理学学院主席。Goodwin博士在牛津大学获得了学士、DPhil、BM和BCH。
Guy Goodwin,has served as Chief Medical Officer since August 2021. Dr. Goodwin currently serves as Emeritus Professor of Psychiatry at The University of Oxford, where he has been a professor of psychiatry since October 1996. Additionally, Dr. Goodwin served as Medical Director at P1vital, where he worked between April 2018 and July 2021. Dr. Goodwin previously served as WA Handley Chair of Psychiatry and Head of the University of Oxford's Department of Psychiatry. Dr. Goodwin is a Fellow of the Academy of Medical Sciences, the American College of Neuropsychopharmacology, and former President of the British Association for Psychopharmacology and of the European College of Neuropsychopharmacology. Dr. Goodwin received his BA, DPhil, BM, and BCh from the University of Oxford.- Guy Goodwin，自2021年8月起担任首席医疗官。古德温博士目前担任牛津大学精神病学名誉教授，自1996年10月起担任该大学精神病学教授。此外，古德温博士还曾在P1vital担任医疗主任，他在2018年4月至2021年7月期间在那里工作。古德温博士此前曾担任WA Handley精神病学主席和牛津大学精神病学系主任。古德温博士是美国神经精神药理学学院医学科学院院士，曾任英国心理药理学协会和欧洲神经精神药理学学院主席。Goodwin博士在牛津大学获得了学士、DPhil、BM和BCH。
- Guy Goodwin,has served as Chief Medical Officer since August 2021. Dr. Goodwin currently serves as Emeritus Professor of Psychiatry at The University of Oxford, where he has been a professor of psychiatry since October 1996. Additionally, Dr. Goodwin served as Medical Director at P1vital, where he worked between April 2018 and July 2021. Dr. Goodwin previously served as WA Handley Chair of Psychiatry and Head of the University of Oxford's Department of Psychiatry. Dr. Goodwin is a Fellow of the Academy of Medical Sciences, the American College of Neuropsychopharmacology, and former President of the British Association for Psychopharmacology and of the European College of Neuropsychopharmacology. Dr. Goodwin received his BA, DPhil, BM, and BCh from the University of Oxford.